In contrast, transcriptome analysis and siRNA library showed that diverse epigenetic mechanisms intricately affect the adaptive resistance in ALK-rearranged lung cancer, indicating that EGFR is involved in part of the adaptive response to lorlatinib. This evidence concerns the gene ALK and lung cancer.